ArticleCancer cell international2015
Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp.
Article in Cancer cell international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06429189 (An Online Home-based Combined Exercise Intervention With Self-selected Intensity for Women With Breast Cancer), which is not on this map. Cited by 281 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Online Home-based Combined Exercise Intervention With Self-selected Intensity for Women With Breast Cancer: The Home-Combo Randomized Controlled Trial.
Who cites it
281 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Combination Chemotherapy with Selected Polyphenols in Preclinical and Clinical Studies-An Update Overview.Molecules (Basel, Switzerland) · 2023Pooled it
- Responses of Anti-Apoptotic Molecules to EAgNPs and EAgNPs Plus L-Buthionine-Sulfoximine in Human Tongue Cancer Cells.Molecules (Basel, Switzerland) · 2026Article
- Beta-cyclodextrin-based polymerized nanocarriers for doxorubicin delivery to cancer cells.Nanoscale advances · 2026Article
- Pharmacokinetic studies and synergistic antitumor effects of cannabichromene and cannabidiol in drug-resistant breast cancers.Drug delivery and translational research · 2026Article
- Privileged nitrogen heterocycles in anticancer drug discovery: recent advances on imidazole, indole, and pyrimidine scaffolds.RSC advances · 2026Review
- A HO-1 gene knockout using a NanoCRISPR scaffold suppresses metastasis in mouse models.Nature biomedical engineering · 2026Article
- The Dual Role of ABCG2 Copy Number Variation: A Protective Factor in Cancer Risk, and a Prognostic Marker for Survival in Thai Breast Cancer.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Synergistic Anticancer Activity of Cannabinoids and Terpenes Against Triple-Negative Breast Cancer Resistance.International journal of molecular sciences · 2026Article
- Effective approaches in conquering chemoresistance of glioblastoma: potential for nanoformulations.Drug delivery and translational research · 2026Review
- Investigating the Synergistic Effect of the Cannabis Extract PHEC-66 and Chemotherapeutic Agents on Human Melanoma Cells.International journal of molecular sciences · 2026Article
- COPG1 Is a Selectively Essential Regulator of Cancer Progression and Chemoresistance via Redox Modulation and AKT Signaling.International journal of molecular sciences · 2026Article
- Repurposing Itraconazole in Combination with Chemotherapy and Immune Checkpoint Inhibitor for Cancer.Medical sciences (Basel, Switzerland) · 2026Review
- Cladosporium cladosporioides, endophyte of Strelitzia nicolai, as a new producer of Alternariol monomethyl ether with a potential cytotoxic activity.Scientific reports · 2026Article
- Nanomaterial-Mediated Targeting of Mitochondrial Metabolism: Strategies and Applications in Cancer Therapy.International journal of nanomedicine · 2026Review
- Mitochondria-Targeted TPP-Meroditerpenes Based on Quinopimaric and Dehydroquinopimaric Acids: Synthesis and Evaluation of Cytotoxicity and Antibacterial Activity.Chemistry & biodiversity · 2026Article
- Structural pharmacogenomics of drug-associated SNPs in oral squamous cell carcinoma.Frontiers in genetics · 2026Article
- Unveiling Targeted Approaches to Combat Drug Resistance in Cancer Chemotherapy.Current pharmaceutical design · 2026Review
- Triptonide suppresses the FOXK1/AKT2 axis to reverse malignant phenotype and improve cisplatin efficacy in esophageal squamous cell carcinoma.Genes & genomics · 2025Article
- Navigating Cancer Treatment: A Journey from 2D to 3D Cancer Models and Nanoscale Therapies.ACS pharmacology & translational science · 2025Review
- Deciphering context-specific Axitinib escape pathways via multi-omics and explainable machine learning.Journal of translational medicine · 2025Article
221 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Cancer chemotherapy resistance (MDR) is the innate and/or acquired ability of cancer cells to evade the effects of chemotherapeutics and is one of the most pressing major dilemmas in cancer therapy. Chemotherapy resistance can arise due to several host or tumor-related factors. However, most current research is focused on tumor-specific factors and specifically genes that handle expression of pumps that efflux accumulated drugs inside malignantly transformed types of cells. In this work, we suggest a wider and alternative perspective that sets the stage for a future platform in modifying drug resistance with respect to the treatment of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.